Get started
Author

Arunachalam Sekar

ORCID: 0000-0002-4659-5260
Observed ORCID: 0000-0002-4659-5260
OpenAlex ID: A5064201892
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2022 · Ashish Noronha, Nishanth Belugali Nataraj, et al. · Cancer Discovery · 109
PDF
PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR
2021 · Soma Ghosh, Nishanth Belugali Nataraj, et al. · Cell Reports · 42
Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors
2022 · Nishanth Belugali Nataraj, Ashish Noronha, et al. · Cell Reports · 34
PDF
ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma
2019 · Swati Srivastava, Nishanth Belugali Nataraj, et al. · Cell Reports · 24
PDF
TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis
2021 · Mary L. Uribe, Maik Dahlhoff, et al. · Science Signaling · 22
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab
2023 · Ilaria Marrocco, Suvendu Giri, et al. · Cell Reports Medicine · 16
PDF
Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors
2021 · Yuya Haga, Ilaria Marrocco, et al. · Cancer Research · 15
PDF
Synthesis, characterization, and evaluation of Cd[L-proline]2, a novel histone deacetylase inhibitor that induces epigenetic modification of histone deacetylase isoforms in A549 cells
2017 · Anusha Chidambaram, Arunachalam Sekar, et al. · Investigational New Drugs · 15
Re-epithelialization of cancer cells increases autophagy and DNA damage: Implications for breast cancer dormancy and relapse
2025 · Diana Drago-Garcia, Suvendu Giri, et al. · Science Signaling · 9
TMPRSS2-ERG confers resistance to antiandrogens: mechanism and therapeutic implications
2025 · Arunachalam Sekar, Rishita Chatterjee, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Supplementary Figure from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al. · 1
Nucleoporin-93 overexpression overcomes multiple nucleocytoplsamic trafficking bottlenecks to permit robust metastasis
2020 · Nishanth Nataraj, Ashish Noronha, et al. · 1
PDF
Tumor cell-intrinsic mtDNA instability drives cGAS-dependent temporal remodeling of the melanoma immune microenvironment
2026 · Abate Assefa Bashaw, Ashley D. Winters, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens
2026 · Arunachalam Sekar, Boobash Raj Selvadurai, et al. · EMBO Molecular Medicine
PDF
Inducible re-epithelialization of cancer cells increases autophagy and DNA damage: implications for breast cancer dormancy
2025 · Diana Drago Garcia, Suvendu Giri, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Supplementary Figure from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Data from Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors
2023 · Yuya Haga, Ilaria Marrocco, et al.
Works count: 39
Citation count: 289
H-index: 9
I10-index: 8
Year
Topic
Type